Nebraska receives $5M in federal HIE funding

Nebraska has been awarded $6.8 million by the Office of the National Coordinator (ONC) to continue development of its statewide HIE.

Nebraska Health Information Initiative, the Omaha-based statewide integrator for HIE and leader of the collaborative that developed and implemented Nebraska’s statewide HIE, will receive $5 million of the funds to continue its expansion and development. The remaining money will be used to support additional health IT programs such as behavioral health, public health, technical upgrades and telehealth.

These organizations will eventually integrate through the NeHII platform, which is powered by Axolotl.

The award was provided through the State HIE Cooperative Agreement Program as a part of the American Recovery and Reinvestment Act of 2009 (ARRA), and provides funding to states to establish and implement statewide HIE networks.

The initiative allocated approximately $36 billion to a wide range of health information technology initiatives across the nation. Prior to receiving funding, each recipient undergoes a review and approval process by ONC that determines specific requirements related to planning, governance, financial, technical, operational and policy.

Nebraska’s strategic and operational plans were submitted in March 2010, and after an eight-month review process with ONC, the funding notification was received on Dec. 1.

Live since March 2009, NeHII, a non-profit 501(c)(3) organization, has functioned as a public-private collaborative as an early adopter of HIE. It currently reaches nearly 85 percent of lives in Nebraska and a substantial number of individuals in Nebraska’s six border states.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.